Home LiteratureArticle Details
PMID: 12351683 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity.

Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW

Abstract

Several misfolding diseases commence when a secreted folded protein encounters a partially denaturing microenvironment, enabling its self assembly into amyloid. Although amyloidosis is modulated by numerous environmental and genetic factors, single point mutations within the amyloidogenic protein can dramatically influence disease phenotype. Mutations that destabilize the native state predispose an individual to disease; however, thermodynamic stability alone does not reliably predict disease severity. Here we show that the rate of transthyretin (TTR) tetramer dissociation required for amyloid formation is strongly influenced by mutation (V30M, L55P, T119M, V122I), with rapid rates exacerbating and slow rates reducing amyloidogenicity. Although these rates are difficult to predict a priori, they notably influence disease penetrance and age of onset. L55P TTR exhibits severe pathology because the tetramer both dissociates quickly and is highly destabilized. Even though V30M and L55P TTR are similarly destabilized, the V30M disease phenotype is milder because V30M dissociates more slowly, even slower than wild type (WT). Although WT and V122I TTR have nearly equivalent tetramer stabilities, V122I cardiomyopathy, unlike WT cardiomyopathy, has nearly complete penetrance-presumably because of its 2-fold increase in dissociation rate. We show that the T119M homotetramer exhibits kinetic stabilization and therefore dissociates exceedingly slowly, likely explaining how it functions to protect V30MT119M compound heterozygotes from disease. An understanding of how mutations influence both the kinetics and thermodynamics of misfolding allows us to rationalize the phenotypic diversity of amyloid diseases, especially when considered in concert with other genetic and environmental data.

MeSH Terms
Amyloidosis/metabolism Humans Kinetics Prealbumin/chemistry,metabolism Protein Denaturation Recombinant Proteins/chemistry,metabolism Thermodynamics
Chemicals
Prealbumin Recombinant Proteins
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Hammarström Per
Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road BCC265, La Jolla, CA 92037, USA.
Jiang Xin
Hurshman Amy R
Powers Evan T
Kelly Jeffery W
References (33)
33 references, click to expand
  1. A protein-folding reaction under kinetic control.
    Nature. 1992 Mar 19;356(6366):263-5 PMID: 1552947
  2. Genetic aspects of amyloidosis.
    Adv Hum Genet. 1991;20:69-123, 309-11 PMID: 1839349
  3. A role for destabilizing amino acid replacements in light-chain amyloidosis.
    Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5446-50 PMID: 8202506
  4. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate.
    J Med Genet. 1994 May;31(5):351-4 PMID: 8064809
  5. Transthyretin mutations in health and disease.
    Hum Mutat. 1995;5(3):191-6 PMID: 7599630
  6. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
    Biochemistry. 1995 Oct 17;34(41):13527-36 PMID: 7577941
  7. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
    Biochemistry. 1996 May 21;35(20):6470-82 PMID: 8639594
  8. Alternative conformations of amyloidogenic proteins govern their behavior.
    Curr Opin Struct Biol. 1996 Feb;6(1):11-7 PMID: 8696966
  9. Familial amyloid polyneuropathy: new developments in genetics and treatment.
    Curr Opin Neurol. 1996 Oct;9(5):355-9 PMID: 8894411
  10. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.
    N Engl J Med. 1997 Feb 13;336(7):466-73 PMID: 9017939
  11. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis.
    Nature. 1997 Feb 27;385(6619):787-93 PMID: 9039909
  12. Protein aggregation: folding aggregates, inclusion bodies and amyloid.
    Fold Des. 1998;3(1):R9-23 PMID: 9502314
  13. Unfolded conformations of alpha-lytic protease are more stable than its native state.
    Nature. 1998 Oct 22;395(6704):817-9 PMID: 9796818
  14. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein.
    Biochemistry. 1999 Mar 16;38(11):3258-67 PMID: 10079068
  15. Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants.
    Biochemistry. 1999 May 18;38(20):6419-27 PMID: 10350460
  16. Protein misfolding, evolution and disease.
    Trends Biochem Sci. 1999 Sep;24(9):329-32 PMID: 10470028
  17. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
    Biochemistry. 1999 Oct 12;38(41):13560-73 PMID: 10521263
  18. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?
    Nat Cell Biol. 2000 Jul;2(7):E115-9 PMID: 10878819
  19. Partially unfolded states of beta(2)-microglobulin and amyloid formation in vitro.
    Biochemistry. 2000 Aug 1;39(30):8735-46 PMID: 10913285
  20. A glimpse of a possible amyloidogenic intermediate of transthyretin.
    Nat Struct Biol. 2000 Sep;7(9):754-7 PMID: 10966644
  21. The stability and folding process of amyloidogenic mutant human lysozymes.
    Eur J Biochem. 2001 Jan;268(1):155-9 PMID: 11121116
  22. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution.
    J Mol Biol. 2001 Mar 2;306(4):733-44 PMID: 11243784
  23. Detection of two partially structured species in the folding process of the amyloidogenic protein beta 2-microglobulin.
    J Mol Biol. 2001 Mar 16;307(1):379-91 PMID: 11243826
  24. Folding of prion protein to its native alpha-helical conformation is under kinetic control.
    J Biol Chem. 2001 Jun 8;276(23):19687-90 PMID: 11306559
  25. Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins.
    Protein Sci. 2001 Aug;10(8):1606-13 PMID: 11468357
  26. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.
    Biochemistry. 2001 Sep 25;40(38):11442-52 PMID: 11560492
  27. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy.
    Biochemistry. 2001 Sep 25;40(38):11453-9 PMID: 11560493
  28. Trans-suppression of misfolding in an amyloid disease.
    Science. 2001 Sep 28;293(5539):2459-62 PMID: 11577236
  29. Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro.
    Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13019-24 PMID: 11687657
  30. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis.
    Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14943-8 PMID: 11752443
  31. Energetic landscape of alpha-lytic protease optimizes longevity through kinetic stability.
    Nature. 2002 Jan 17;415(6869):343-6 PMID: 11797014
  32. Fibril in senile systemic amyloidosis is derived from normal transthyretin.
    Proc Natl Acad Sci U S A. 1990 Apr;87(7):2843-5 PMID: 2320592
  33. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.
    Biochemistry. 1992 Sep 15;31(36):8654-60 PMID: 1390650
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
2002-12-10
Epub
2002-00-25
Pages
16427-32
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC139904
Subset
IM
Grants
NIDDK NIH HHS · R01 DK046335 · United States
NIDDK NIH HHS · R37 DK046335 · United States
NIA NIH HHS · T32 AG000080 · United States
NIDDK NIH HHS · DK 46335 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com